Development of a mucosal nanoemulsion-adjuvanted RSV vaccine using recombinant pre-fusion F protein
Ended Project Grant Awarded Last action
- Award ID
- R44AI145431
- Recipient
-
Bluewillow Biologics Inc. UEI RL3UZ5ZDKFT8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,573,532
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Michigan, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$1,343,901 | |
| Amendment | $891,695 | |
| Amendment | $0 | |
| Amendment | $872,585 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $853,503 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $299,650 |
Quick answers
Who received award R44AI145431?
R44AI145431 was awarded to Bluewillow Biologics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 28, 2020.
How much is award R44AI145431 worth?
$1,573,532 has been obligated on R44AI145431.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award